Download PDF
Semin Respir Crit Care Med 2015; 36(05): 662-672
DOI: 10.1055/s-0035-1562893
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Invasive Aspergillosis: Epidemiology, Clinical Aspects, and Treatment

Kevin S. Gregg
1   Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
,
Carol A. Kauffman
1   Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
2   Division of Infectious Diseases, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan
› Author Affiliations
Further Information

Publication History

Publication Date:
23 September 2015 (online)

    Permissions and Reprints

Abstract

Invasive aspergillosis remains an often fatal, difficult-to treat infection in immunocompromised patients. Patients not classically defined as immunocompromised, especially those in an intensive care unit setting, also develop invasive aspergillosis. Clinical clues suggesting angioinvasion and radiographic modalities, especially computed tomographic scans, combined with newer non–culture-based diagnostic techniques, have allowed earlier recognition of invasive aspergillosis. Although mortality remains high, it has greatly decreased over the past 15 years. Voriconazole has supplanted amphotericin B, with its various toxicities, as primary treatment for invasive aspergillosis. Combination therapy with voriconazole and an echinocandin for initial therapy, based on results from a recent controlled clinical trial, could become the standard of care in high-risk patients.

Keywords

aspergillosis - Aspergillus fumigatus - voriconazole - echinocandins - amphotericin B - epidemiology - hematopoietic cell transplant - solid-organ transplant
 

  • References

  • 1 Segal BH. Aspergillosis. N Engl J Med 2009; 360 (18) 1870-1884
    CrossrefPubMedGoogle Scholar
  • 2 Cornely OA, Maertens J, Winston DJ , et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356 (4) 348-359
    CrossrefPubMedGoogle Scholar
  • 3 Ullmann AJ, Lipton JH, Vesole DH , et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356 (4) 335-347
    CrossrefPubMedGoogle Scholar
  • 4 Baddley JW. Clinical risk factors for invasive aspergillosis. Med Mycol 2011; 49 (Suppl. 01) S7-S12
    CrossrefPubMedGoogle Scholar
  • 5 Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005; 43 (Suppl. 01) S207-S238
    CrossrefPubMedGoogle Scholar
  • 6 Nicolle M-C, Benet T, Vanhems P. Aspergillosis: nosocomial or community-acquired?. Med Mycol 2011; 49 (Suppl. 01) S24-S29
    CrossrefPubMedGoogle Scholar
  • 7 Patterson TF, Kirkpatrick WR, White M , et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79 (4) 250-260
    CrossrefPubMedGoogle Scholar
  • 8 Perfect JR, Cox GM, Lee JY , et al; Mycoses Study Group. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33 (11) 1824-1833
    CrossrefPubMedGoogle Scholar
  • 9 Kontoyiannis DP, Marr KA, Park BJ , et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50 (8) 1091-1100
    CrossrefPubMedGoogle Scholar
  • 10 Pappas PG, Alexander BD, Andes DR , et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50 (8) 1101-1111
    CrossrefPubMedGoogle Scholar
  • 11 Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26 (4) 781-803 , quiz 804–805
    CrossrefPubMedGoogle Scholar
  • 12 Bochud PY, Chien JW, Marr KA , et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359 (17) 1766-1777
    CrossrefPubMedGoogle Scholar
  • 13 Cunha C, Di Ianni M, Bozza S , et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 2010; 116 (24) 5394-5402
    CrossrefPubMedGoogle Scholar
  • 14 Chai LY, de Boer MG, van der Velden WJ , et al. The Y238X stop codon polymorphism in the human β-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J Infect Dis 2011; 203 (5) 736-743
    CrossrefPubMedGoogle Scholar
  • 15 Cunha C, Aversa F, Lacerda JF , et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med 2014; 370 (5) 421-432
    CrossrefPubMedGoogle Scholar
  • 16 Chakrabarti A, Chatterjee SS, Das A, Shivaprakash MR. Invasive aspergillosis in developing countries. Med Mycol 2011; 49 (Suppl. 01) S35-S47
    CrossrefPubMedGoogle Scholar
  • 17 Yuen K-Y, Woo PCY, Ip MSM , et al. Stage-specific manifestation of mold infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears. Clin Infect Dis 1997; 25 (1) 37-42
    CrossrefPubMedGoogle Scholar
  • 18 Iwen PC, Rupp ME, Langnas AN, Reed EC, Hinrichs SH. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis 1998; 26 (5) 1092-1097
    CrossrefPubMedGoogle Scholar
  • 19 Baddley JW, Pappas PG, Smith AC, Moser SA. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol 2003; 41 (12) 5525-5529
    CrossrefPubMedGoogle Scholar
  • 20 Steinbach WJ, Benjamin Jr DK, Kontoyiannis DP , et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39 (2) 192-198
    CrossrefPubMedGoogle Scholar
  • 21 Panackal AA, Imhof A, Hanley EW, Marr KA. Aspergillus ustus infections among transplant recipients. Emerg Infect Dis 2006; 12 (3) 403-408
    CrossrefPubMedGoogle Scholar
  • 22 Pavie J, Lacroix C, Hermoso DG , et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 2005; 43 (9) 4902-4904
    CrossrefPubMedGoogle Scholar
  • 23 Riddell Iv J, McNeil SA, Johnson TM, Bradley SF, Kazanjian PH, Kauffman CA. Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature. Medicine (Baltimore) 2002; 81 (4) 311-320
    CrossrefPubMedGoogle Scholar
  • 24 Henriet SSV, Verweij PE, Warris A. Aspergillus nidulans and chronic granulomatous disease: a unique host-pathogen interaction. J Infect Dis 2012; 206 (7) 1128-1137
    CrossrefPubMedGoogle Scholar
  • 25 Blumental S, Mouy R, Mahlaoui N , et al. Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Clin Infect Dis 2011; 53 (12) e159-e169
    CrossrefPubMedGoogle Scholar
  • 26 Perdelli F, Cristina ML, Sartini M , et al. Fungal contamination in hospital environments. Infect Control Hosp Epidemiol 2006; 27 (1) 44-47
    CrossrefPubMedGoogle Scholar
  • 27 Thio CL, Smith D, Merz WG , et al. Refinements of environmental assessment during an outbreak investigation of invasive aspergillosis in a leukemia and bone marrow transplant unit. Infect Control Hosp Epidemiol 2000; 21 (1) 18-23
    CrossrefPubMedGoogle Scholar
  • 28 Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment—rethinking our approach to prevention. Clin Infect Dis 2001; 33 (9) 1549-1552
    CrossrefPubMedGoogle Scholar
  • 29 Anaissie EJ, Stratton SL, Dignani MC , et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002; 34 (6) 780-789
    CrossrefPubMedGoogle Scholar
  • 30 Warnock DW, Hajjeh RA, Lasker BA. Epidemiology and prevention of invasive aspergillosis. Curr Infect Dis Rep 2001; 3 (6) 507-516
    CrossrefPubMedGoogle Scholar
  • 31 Bouakline A, Lacroix C, Roux N, Gangneux JP, Derouin F. Fungal contamination of food in hematology units. J Clin Microbiol 2000; 38 (11) 4272-4273
    PubMedGoogle Scholar
  • 32 Marks WH, Florence L, Lieberman J , et al. Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Transplantation 1996; 61 (12) 1771-1774
    CrossrefPubMedGoogle Scholar
  • 33 Lass-Flörl C, Rath P, Niederwieser D , et al. Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. J Hosp Infect 2000; 46 (1) 31-35
    CrossrefPubMedGoogle Scholar
  • 34 Vonberg RP, Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect 2006; 63 (3) 246-254
    CrossrefPubMedGoogle Scholar
  • 35 Segal BH, Bow EJ, Menichetti F. Fungal infections in nontransplant patients with hematologic malignancies. Infect Dis Clin North Am 2002; 16 (4) 935-964 , vii
    CrossrefPubMedGoogle Scholar
  • 36 Nucci M, Garnica M, Gloria AB , et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect 2013; 19 (8) 745-751
    CrossrefPubMedGoogle Scholar
  • 37 Neofytos D, Treadway S, Ostrander D , et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis 2013; 15 (3) 233-242
    CrossrefPubMedGoogle Scholar
  • 38 Lortholary O, Ascioglu S, Moreau P , et al. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Français du Myélome. Clin Infect Dis 2000; 30 (1) 41-46
    CrossrefPubMedGoogle Scholar
  • 39 Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47 (8) 1041-1050
    CrossrefPubMedGoogle Scholar
  • 40 Miyakoshi S, Kusumi E, Matsumura T , et al. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. Biol Blood Marrow Transplant 2007; 13 (7) 771-777
    CrossrefPubMedGoogle Scholar
  • 41 Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100 (13) 4358-4366
    CrossrefPubMedGoogle Scholar
  • 42 Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34 (2) 115-121
    CrossrefPubMedGoogle Scholar
  • 43 Marty FM, Lee SJ, Fahey MM , et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102 (8) 2768-2776
    CrossrefPubMedGoogle Scholar
  • 44 Cordonnier C, Ribaud P, Herbrecht R , et al; Société Française de Greffe de Moelle et de Thérapie Cellulaire. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42 (7) 955-963
    CrossrefPubMedGoogle Scholar
  • 45 Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44 (4) 531-540
    CrossrefPubMedGoogle Scholar
  • 46 Lortholary O, Gangneux JP, Sitbon K , et al; French Mycosis Study Group. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin Microbiol Infect 2011; 17 (12) 1882-1889
    CrossrefPubMedGoogle Scholar
  • 47 Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170 (6) 621-625
    CrossrefPubMedGoogle Scholar
  • 48 Baddley JW, Stephens JM, Ji X, Gao X, Schlamm HT, Tarallo M. Aspergillosis in intensive care unit (ICU) patients: epidemiology and economic outcomes. BMC Infect Dis 2013; 13: 29
    CrossrefPubMedGoogle Scholar
  • 49 Meersseman W, Van Wijngaerden E. Invasive aspergillosis in the ICU: an emerging disease. Intensive Care Med 2007; 33 (10) 1679-1681
    CrossrefPubMedGoogle Scholar
  • 50 Falcone M, Massetti AP, Russo A, Vullo V, Venditti M. Invasive aspergillosis in patients with liver disease. Med Mycol 2011; 49 (4) 406-413
    CrossrefPubMedGoogle Scholar
  • 51 Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008; 83 (2) 181-194
    CrossrefPubMedGoogle Scholar
  • 52 Park SY, Kim SH, Choi SH , et al. Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients. Transpl Infect Dis 2010; 12 (4) 309-315
    CrossrefPubMedGoogle Scholar
  • 53 Fernández-Ruiz M, Silva JT, San-Juan R , et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature. Medicine (Baltimore) 2012; 91 (5) 261-273
    CrossrefPubMedGoogle Scholar
  • 54 He H, Jiang S, Zhang L , et al. Aspergillus tracheobronchitis in critically ill patients with chronic obstructive pulmonary diseases. Mycoses 2014; 57 (8) 473-482
    CrossrefPubMedGoogle Scholar
  • 55 Greene RE, Schlamm HT, Oestmann JW , et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44 (3) 373-379
    CrossrefPubMedGoogle Scholar
  • 56 Kuhlman JE, Fishman EK, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis. Radiology 1985; 157 (3) 611-614
    CrossrefPubMedGoogle Scholar
  • 57 Shibuya K, Ando T, Hasegawa C , et al. Pathophysiology of pulmonary aspergillosis. J Infect Chemother 2004; 10 (3) 138-145
    CrossrefPubMedGoogle Scholar
  • 58 Caillot D, Couaillier JF, Bernard A , et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19 (1) 253-259
    CrossrefPubMedGoogle Scholar
  • 59 Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011; 52 (9) 1144-1155
    CrossrefPubMedGoogle Scholar
  • 60 Yeghen T, Kibbler CC, Prentice HG , et al. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis 2000; 31 (4) 859-868
    CrossrefPubMedGoogle Scholar
  • 61 Reichenberger F, Habicht JM, Gratwohl A, Tamm M. Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 2002; 19 (4) 743-755
    CrossrefPubMedGoogle Scholar
  • 62 Lim C, Seo JB, Park SY , et al. Analysis of initial and follow-up CT findings in patients with invasive pulmonary aspergillosis after solid organ transplantation. Clin Radiol 2012; 67 (12) 1179-1186
    CrossrefPubMedGoogle Scholar
  • 63 Dai Z, Zhao H, Cai S, Lv Y, Tong W. Invasive pulmonary aspergillosis in non-neutropenic patients with and without underlying disease: a single-centre retrospective analysis of 52 subjects. Respirology 2013; 18 (2) 323-331
    CrossrefPubMedGoogle Scholar
  • 64 Cornillet A, Camus C, Nimubona S , et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43 (5) 577-584
    CrossrefPubMedGoogle Scholar
  • 65 Walsh TJ, Anaissie EJ, Denning DW , et al; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46 (3) 327-360
    CrossrefPubMedGoogle Scholar
  • 66 Marr KA, Schlamm HT, Herbrecht R , et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015; 162 (2) 81-89
    CrossrefPubMedGoogle Scholar
  • 67 Herbrecht R, Denning DW, Patterson TF , et al; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347 (6) 408-415
    CrossrefPubMedGoogle Scholar
  • 68 De Pauw B, Walsh TJ, Donnelly JP , et al; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46 (12) 1813-1821
    CrossrefPubMedGoogle Scholar
  • 69 Herbrecht R, Patterson TF, Slavin MA , et al. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis 2015; 60 (5) 713-720
    CrossrefPubMedGoogle Scholar
  • 70 Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc 2011; 86 (8) 805-817
    CrossrefPubMedGoogle Scholar
  • 71 Neofytos D, Lombardi LR, Shields RK , et al. Administration of voriconazole in patients with renal dysfunction. Clin Infect Dis 2012; 54 (7) 913-921
    CrossrefPubMedGoogle Scholar
  • 72 Levin MD, den Hollander JG, van der Holt B , et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother 2007; 60 (5) 1104-1107
    CrossrefPubMedGoogle Scholar
  • 73 Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46 (2) 201-211
    CrossrefPubMedGoogle Scholar
  • 74 Smith J, Safdar N, Knasinski V , et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50 (4) 1570-1572
    CrossrefPubMedGoogle Scholar
  • 75 Park WB, Kim NH, Kim KH , et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55 (8) 1080-1087
    CrossrefPubMedGoogle Scholar
  • 76 Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007; 45 (12) 1610-1617
    CrossrefPubMedGoogle Scholar
  • 77 Walsh TJ, Raad I, Patterson TF , et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44 (1) 2-12
    CrossrefPubMedGoogle Scholar
  • 78 Heinz WJ, Egerer G, Lellek H, Boehme A, Greiner J. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses 2013; 56 (3) 304-310
    CrossrefPubMedGoogle Scholar
  • 79 Jung DS, Tverdek FP, Kontoyiannis DP. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother 2014; 58 (11) 6993-6995
    CrossrefPubMedGoogle Scholar
  • 80 Seyedmousavi S, Mouton JW, Verweij PE, Brüggemann RJ. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther 2013; 11 (9) 931-941
    CrossrefPubMedGoogle Scholar
  • 81 Bates DW, Su L, Yu DT , et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32 (5) 686-693
    CrossrefPubMedGoogle Scholar
  • 82 Wingard JR, Kubilis P, Lee L , et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29 (6) 1402-1407
    CrossrefPubMedGoogle Scholar
  • 83 Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2014; 9: CD000969
    PubMedGoogle Scholar
  • 84 Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36 (11) 1445-1457
    CrossrefPubMedGoogle Scholar
  • 85 Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42 (8) 1171-1178
    CrossrefPubMedGoogle Scholar
  • 86 Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006; 43 (2) 215-222
    CrossrefPubMedGoogle Scholar
  • 87 Maertens J, Raad I, Petrikkos G , et al; Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39 (11) 1563-1571
    CrossrefPubMedGoogle Scholar
  • 88 Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005; 50 (3) 196-205
    CrossrefPubMedGoogle Scholar
  • 89 Morrissey CO, Slavin MA, O'Reilly MA , et al. Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. Mycoses 2007; 50 (Suppl. 01) 24-37
    CrossrefPubMedGoogle Scholar
  • 90 Denning DW, Marr KA, Lau WM , et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53 (5) 337-349
    CrossrefPubMedGoogle Scholar
  • 91 Herbrecht R, Maertens J, Baila L , et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; 45 (7) 1227-1233
    CrossrefPubMedGoogle Scholar
  • 92 Viscoli C, Herbrecht R, Akan H , et al; Infectious Disease Group of the EORTC. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64 (6) 1274-1281
    CrossrefPubMedGoogle Scholar
  • 93 Cornely OA, Vehreschild JJ, Vehreschild MJGT , et al. Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother 2011; 55 (12) 5798-5803
    CrossrefPubMedGoogle Scholar
  • 94 Martín-Peña A, Aguilar-Guisado M, Espigado I, Cisneros JM. Antifungal combination therapy for invasive aspergillosis. Clin Infect Dis 2014; 59 (10) 1437-1445
    CrossrefPubMedGoogle Scholar
  • 95 Aliff TB, Maslak PG, Jurcic JG , et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97 (4) 1025-1032
    CrossrefPubMedGoogle Scholar
  • 96 Kontoyiannis DP, Hachem R, Lewis RE , et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98 (2) 292-299
    CrossrefPubMedGoogle Scholar
  • 97 Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39 (6) 797-802
    CrossrefPubMedGoogle Scholar
  • 98 Singh N, Limaye AP, Forrest G , et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81 (3) 320-326
    CrossrefPubMedGoogle Scholar
  • 99 Maertens J, Glasmacher A, Herbrecht R , et al; Caspofungin Combination Therapy Study Group. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107 (12) 2888-2897
    CrossrefPubMedGoogle Scholar
  • 100 Caillot D, Thiébaut A, Herbrecht R , et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007; 110 (12) 2740-2746
    CrossrefPubMedGoogle Scholar
  • 101 Raad II, Hanna HA, Boktour M , et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008; 22 (3) 496-503
    CrossrefPubMedGoogle Scholar
  • 102 Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23 (3) 608-615
    CrossrefPubMedGoogle Scholar
  • 103 Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32 (3) 358-366
    CrossrefPubMedGoogle Scholar
  • 104 Muñoz P, Cerón I, Valerio M , et al. Invasive aspergillosis among heart transplant recipients: a 24-year perspective. J Heart Lung Transplant 2014; 33 (3) 278-288
    CrossrefPubMedGoogle Scholar
  • 105 Baddley JW, Andes DR, Marr KA , et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50 (12) 1559-1567
    CrossrefPubMedGoogle Scholar
  • 106 Neofytos D, Horn D, Anaissie E , et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48 (3) 265-273
    CrossrefPubMedGoogle Scholar
  • 107 Barchiesi F, Mazzocato S, Mazzanti S , et al. Invasive aspergillosis in liver transplant recipients: epidemiology, clinical characteristics, treatment and outcome in 116 cases. Liver Transpl 2015; 21 (2) 204-212
    CrossrefPubMedGoogle Scholar
  • 108 Singh N, Suarez JF, Avery R , et al. Risk factors and outcomes in lung transplant recipients with nodular invasive pulmonary aspergillosis. J Infect 2013; 67 (1) 72-78
    CrossrefPubMedGoogle Scholar
  • 109 Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect 2004; 56 (4) 269-276
    CrossrefPubMedGoogle Scholar
  • 110 Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 30 (4) 782-800
    CrossrefPubMedGoogle Scholar